{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:15:36Z","timestamp":1782738936027,"version":"3.54.5"},"reference-count":44,"publisher":"Scientific Scholar","content-domain":{"domain":["cytojournal.com"],"crossmark-restriction":true},"short-container-title":["Cytojournal"],"abstract":"\nObjective:<\/jats:title>\nMultiple myeloma (MM) is a bone marrow cancer that profoundly affects plasma cells involved in the immune response. Myeloma cells alter the average production of cells in the bone marrow. Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy allows genetic modifications of an individual\u2019s T-cells to increase the expression of CARs used to identify and attach BCMA proteins to the malignant cells. Our main objective is to perform a systematic review and meta-analysis to explore the efficacy and safety of anti-BCMA CAR T-cell therapy for MM.<\/jats:p>\n<\/jats:sec>\n\nMaterial and Methods:<\/jats:title>\nWe searched five databases, PubMed, CNKI, EMBASE, Cochrane, Web of Science, and CNKI, for studies published on anti-BCMA,CAR-T-cell treatment for MM. Inclusion criteria involved prospective single-arm studies either single or multi-center, in various MM phases and studies that reported anti-BCMA,CAR-T-cell treatment for MM. We excluded non-English publications and conference papers. All statistical analyses were performed in R software and Review Manager 5.4.1.<\/jats:p>\n<\/jats:sec>\n\nResults:<\/jats:title>\nThirteen articles were included in the analysis. We found that the overall response survival complete response increase was statistically significant. Similarly, the reduction in cytokine release syndrome grades 3 and 4 and neurotoxicity after follow-up was statistically significant. However, the reduction in minimal residual disease negativity (MRDN) was not statistically significant.<\/jats:p>\n<\/jats:sec>\n\nConclusion:<\/jats:title>\nUsing anti-BCMA CAR T-cell therapy in MM was highly efficacious and safe in lowering the adverse outcomes and improving the survival outcomes, complete response, and overall response.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/cytojournal_64_2023","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T08:23:51Z","timestamp":1710750231000},"page":"13","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Exploring the efficacy and safety of anti-BCMA chimeric antigen receptor T-cell therapy for multiple myeloma: Systematic review and meta-analysis"],"prefix":"10.25259","volume":"21","author":[{"given":"Jia","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, China,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tiantai People\u2019s Hospital of Zhejiang Province, Taizhou, China,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"10.25259\/Cytojournal_64_2023\/ref-1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjh.15003","article-title":"Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders","volume":"180","author":"Foulk","year":"2018","journal-title":"Br J Haematol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-2","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: Emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.25259\/Cytojournal_64_2023\/ref-3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjh.16764","article-title":"The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: Is it time for a paradigm shift?","volume":"191","author":"Kazandjian","year":"2020","journal-title":"Br J Haematol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.25259\/Cytojournal_64_2023\/ref-5","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.25259\/Cytojournal_64_2023\/ref-6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric antigen receptor-modified T cell therapy in multiple myeloma: Beyond B cell maturation antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front Immunol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-7","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00277-018-03592-9","article-title":"Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma","volume":"98","author":"Ma","year":"2019","journal-title":"Ann Hematol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?","volume":"34","author":"D'Agostino","year":"2020","journal-title":"Leukemia"},{"key":"10.25259\/Cytojournal_64_2023\/ref-10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2021","journal-title":"Future Oncol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-11","doi-asserted-by":"publisher","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front Immunol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: Phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.25259\/Cytojournal_64_2023\/ref-13","author":"Nam","year":"2019"},{"key":"10.25259\/Cytojournal_64_2023\/ref-14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5152\/tao.2019.4058","article-title":"A guide for systematic reviews: PRISMA","volume":"57","author":"Sel\u00e7uk","year":"2019","journal-title":"Turk Arch Otorhinolaryngol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-15","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume-title":"Cochrane Database Syst Rev","volume":"10","author":"Cumpston","year":"2019"},{"key":"10.25259\/Cytojournal_64_2023\/ref-16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2020.12.017","article-title":"A modified Newcastle-Ottawa scale for assessment of study quality in genetic urological research","volume":"79","author":"Norris","year":"2021","journal-title":"Eur Urol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-17","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-19","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.clml.2019.09.034","article-title":"Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"19","author":"Li","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.25259\/Cytojournal_64_2023\/ref-20","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.25259\/Cytojournal_64_2023\/ref-21","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2018","journal-title":"Proc Nat Acad Sci U S A"},{"key":"10.25259\/Cytojournal_64_2023\/ref-22","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.25259\/Cytojournal_64_2023\/ref-23","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"10.25259\/Cytojournal_64_2023\/ref-24","doi-asserted-by":"publisher","first-page":"120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"10.25259\/Cytojournal_64_2023\/ref-25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"key":"10.25259\/Cytojournal_64_2023\/ref-26","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated k light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Investig"},{"key":"10.25259\/Cytojournal_64_2023\/ref-27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.25259\/Cytojournal_64_2023\/ref-28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan","year":"2021","journal-title":"Cancer Med"},{"key":"10.25259\/Cytojournal_64_2023\/ref-29","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-30","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3390\/cimb44040098","article-title":"sBCMA plasma LEVEL dynamics and anti-BCMA CAR-T-cell treatment in relapsed multiple myeloma","volume":"44","author":"Seipel","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-31","doi-asserted-by":"publisher","first-page":"620312","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: An overview of experience from clinical trials, pathophysiology, and management strategies","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-32","first-page":"3285","article-title":"A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"11","author":"Cornell","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.25259\/Cytojournal_64_2023\/ref-33","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor t cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.25259\/Cytojournal_64_2023\/ref-34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-36","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"10.25259\/Cytojournal_64_2023\/ref-37","doi-asserted-by":"publisher","first-page":"11185","DOI":"10.1038\/s41598-022-15455-5","article-title":"A novel lipidic peptide with potential to promote balanced effector-regulatory T cell responses","volume":"12","author":"Agrez","year":"2022","journal-title":"Sci Rep"},{"key":"10.25259\/Cytojournal_64_2023\/ref-38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","article-title":"Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with MM target cells","volume":"15","author":"Tan","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-39","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-40","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1182\/blood-2019-130340","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma: Updated results from a phase 1 dose-climbing trial","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"10.25259\/Cytojournal_64_2023\/ref-41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.13015","article-title":"On the road to eliminating long-lived plasma cells-\"are we there yet?","volume":"303","author":"Markmann","year":"2021","journal-title":"\" Immunol Rev"},{"key":"10.25259\/Cytojournal_64_2023\/ref-42","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia"},{"key":"10.25259\/Cytojournal_64_2023\/ref-43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.25259\/Cytojournal_64_2023\/ref-44","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.bbmt.2020.04.008","article-title":"Chimeric antigen receptor T cell therapy during the COVID-19 pandemic","volume":"26","author":"Bachanova","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cytojournal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cytojournal.com\/exploring-the-efficacy-and-safety-of-anti-bcma-chimeric-antigen-receptor-t-cell-therapy-for-multiple-myeloma-systematic-review-and-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cytojournal.com\/exploring-the-efficacy-and-safety-of-anti-bcma-chimeric-antigen-receptor-t-cell-therapy-for-multiple-myeloma-systematic-review-and-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T18:13:21Z","timestamp":1734545601000},"score":1,"resource":{"primary":{"URL":"https:\/\/cytojournal.com\/exploring-the-efficacy-and-safety-of-anti-bcma-chimeric-antigen-receptor-t-cell-therapy-for-multiple-myeloma-systematic-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":44,"alternative-id":["10.25259\/Cytojournal_64_2023"],"URL":"https:\/\/doi.org\/10.25259\/cytojournal_64_2023","relation":{},"ISSN":["1742-6413","0974-5963"],"issn-type":[{"value":"1742-6413","type":"electronic"},{"value":"0974-5963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"article-number":"13"}}